Nincs elég ideje elolvasni a teljes cikket? Hallgassa meg az összefoglalót 2 percben.

A European pharmaceutical company recently decided to move production of a mature product from one plant to another.

The process had been running successfully for years. Documentation was complete. Analytical methods were validated. The receiving plant had similar equipment and a strong regulatory history.

On paper the transfer looked routine.

The timeline suggested that commercial production could begin within twelve months.

Yet eighteen months later the program was still struggling. Validation batches had to be repeated. Minor process deviations kept appearing. Engineering adjustments delayed production campaigns.

Nothing dramatic had gone wrong.

But progress had quietly slowed to a crawl.

Situations like this are far more common in pharmaceutical manufacturing than many organizations expect.

The assumption behind most tech transfers

Most companies approach tech transfer with a simple assumption.

If the process works in one plant, it should work in another.

In theory this makes sense. The scientific knowledge already exists. The manufacturing parameters are documented. The analytical methods are defined.

But in practice, pharmaceutical manufacturing processes behave differently once they enter a new operational environment.

Even small differences can affect outcomes:

• equipment configuration
• environmental conditions
• operator routines
• raw material suppliers
• automation settings

Individually these variations appear manageable.

Together they create operational friction once the first batches are produced.

Expectation vs operational reality

What corporate teams expect during a transfer is usually predictable.

Process documentation moves from the sending site to the receiving site. Engineering teams confirm equipment compatibility. Validation batches demonstrate that the process performs as expected.

In reality, the first months inside the receiving plant look very different.

Process yields fluctuate. Operators discover subtle differences in equipment behaviour. Quality teams raise documentation questions that were never discussed during planning.

The transfer program gradually moves from a documentation exercise to a full operational challenge.

At that point the project begins competing with the plant’s everyday responsibilities.

When the receiving plant reaches its limits

Most pharmaceutical plants that receive tech transfers are already operating near capacity.

Production schedules must continue running. Regulatory inspections still occur. Quality systems must remain stable.

Adding a transfer program into this environment creates competing priorities.

Plant leaders suddenly face difficult choices.

Should engineering resources support the transfer or ongoing production?

Should validation batches take priority over commercial supply commitments?

How quickly should quality teams approve process adjustments?

These questions require operational decisions, not project coordination.

The moment tech transfers start drifting

In many struggling programs, the early warning signs are subtle.

Progress does not stop completely. Instead, timelines begin expanding.

A useful diagnostic question is simple:

Is the transfer still moving at the speed originally planned?

When delays accumulate, the underlying causes usually appear in three areas:

1. Process instability

The receiving site struggles to reproduce the exact performance seen at the original plant.

2. Cross-functional friction

Engineering, production and quality teams move at different speeds.

3. Decision delays

No single leader has authority to resolve operational conflicts.

When these factors combine, the transfer program begins losing momentum.

Why project management cannot solve this alone

Many pharmaceutical companies structure transfer programs around project management frameworks.

Project managers track timelines, coordinate meetings between sites, and monitor deliverables.

This coordination is necessary.

But it does not solve operational conflicts.

When production priorities clash with validation timelines, someone must decide which activity takes precedence. When engineering modifications affect quality documentation, someone must align both teams quickly.

Without operational authority, these decisions drift across organizational boundaries.

The project continues moving forward, but more slowly with each passing month.

Where interim operational leadership changes the trajectory

This is often the point where companies introduce ideiglenes operatív vezetés.

Interim leaders step directly into roles such as Interim Plant Director or Interim Operations Executive. Their mandate is not advisory.

It is execution.

An experienced interim leader can quickly align engineering, manufacturing and quality functions around a single operational plan. They can prioritise plant resources, accelerate validation decisions and ensure that the transfer program moves forward without destabilising existing production.

Because interim leaders operate inside the organization rather than outside it, they can resolve conflicts that project structures alone cannot.

In many cases, restoring operational ownership is the turning point that allows the transfer to finally reach commercial production.

Tech transfer is an operational leadership test

Pharmaceutical companies will continue transferring products between plants. Manufacturing networks evolve constantly as companies expand capacity, optimise supply chains and respond to regulatory pressures.

Every transfer involves technical knowledge.

But successful transfers ultimately depend on something less visible.

They depend on whether a receiving plant can organise its people, systems and decisions around executing the new process reliably.

That is not a documentation challenge.

It is an operational leadership challenge.